Nanalyze Says Cannabis Stocks Look Cheap. Here's What to Check

What Nanalyze published, and what we can verify

Nanalyze's Oct. 16, 2026 piece frames cannabis equities as cheap, but the headline is the only part CannIntel could independently confirm.

The investor-research site ran the article under the title "Why Cannabis Stocks Are Looking Dirt Cheap." We worked from the headline and publication metadata, not the full text. So we aren't repeating any multiples, price targets or company-level figures from the piece.

Cheap against what? That's the question every valuation call in this sector has to answer, and it's where the analysis below starts.

Cheap is a denominator problem

A low multiple says little until you know how much reported profit survives tax, financing costs and compliance overhead.

The biggest drag is Section 280E of the Internal Revenue Code, which bars businesses that traffic in Schedule I or II substances from deducting ordinary operating expenses. Plant-touching operators end up taxed closer to gross profit than net profit. So a stock trading at a modest multiple of EBITDA can still look expensive on after-tax free cash flow.

That's the trap in any "dirt cheap" headline. A discount on paper isn't a discount in practice if the earnings line is generous and the cash line isn't.

The tech stack is a cost line investors rarely model

Software, payments and state tracking systems are fixed costs that weigh on margins in oversupplied markets.

Every licensed operator runs a state-mandated seed-to-sale system, and in many states that means Metrc or BioTrack, while retailers typically layer a POS and e-commerce platform such as Dutchie, Treez or Flowhub on top of it. Pricing is usually a per-location subscription, with payment processing and add-on modules billed separately.

Payments are the messier piece. Federal illegality keeps mainstream card networks at arm's length, so many dispensaries rely on cash, PIN debit workarounds or cashless ATM setups, each with its own fee structure. Those fees come out of the same margin that 280E already squeezes.

Analysts who screen on revenue multiples alone miss all of it. Operators with tighter stacks and lower processing costs can look similar on a screen and perform very differently.

Rescheduling is the swing variable, not the only one

A move to Schedule III would remove 280E exposure for plant-touching operators, but it wouldn't by itself fix capital access.

Any shift of marijuana to Schedule III through the DEA process would, in theory, let operators deduct normal business expenses again and lift after-tax cash flow. That's the bull case behind most cheap-stock arguments. The timing and final shape of that change remain the biggest variable for the sector's valuation.

Rescheduling doesn't, however, put multistate operators on the NYSE or Nasdaq. U.S. plant-touching companies still list mainly on the Canadian Securities Exchange and trade over the counter in the U.S., which limits the pool of institutional buyers. Federal banking reform is a separate fight.

State fundamentals matter too. Oversupplied, price-compressed markets such as California behave very differently from limited-license states like Ohio, so a basket of "cheap" MSOs can hide wildly different unit economics.

How to pressure-test a "cheap" call

Treat any cannabis valuation claim as three separate questions: after-tax earnings, balance-sheet runway and state mix.

Start with cash taxes paid versus book taxes, since the gap shows how much 280E is really costing. Then look at debt maturities, because refinancing risk can swamp a low multiple. Finally, check where revenue comes from, because a company concentrated in one compressed market deserves a lower multiple than one spread across limited-license states.

Operators should run the same test internally. If your POS, compliance and payment vendors cost more than your last contract review assumed, that's margin you can recover before any federal policy change helps you. For full background on how the sector is being priced, see the CannIntel topic hub on cannabis stocks valuation.

The next signal to watch is the DEA's rescheduling timeline, followed by the first quarterly filings that show cash taxes paid. If 280E relief arrives, those cash-tax lines will show whether "cheap" was real.